Results 231 to 240 of about 13,150,510 (391)
CHEMICAL PROCESSING TECHNOLOGY QUARTERLY PROGRESS REPORT, JANUARY-MARCH 1963
J.R. ed. Bower
openalex +2 more sources
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho+11 more
wiley +1 more source
Economic and sustainable revolution to facilitate one-carbon biomanufacturing. [PDF]
Zhang C+5 more
europepmc +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp+13 more
wiley +1 more source
The Development and Toxicological Evaluation of Novel Polyurethane Materials. [PDF]
Zhang M+6 more
europepmc +1 more source
CHEMICAL PROCESSING TECHNOLOGY QUARTERLY PROGRESS REPORT, OCTOBER-DECEMBER 1960
J.R. ed. Bower
openalex +2 more sources
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Author Correction: Structural and functional evidence that GPR30 is not a direct estrogen receptor. [PDF]
Liu H+11 more
europepmc +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias+12 more
wiley +1 more source
Silver Nanoparticles for Biosensing and Drug Delivery: A Mechanical Study on DNA Interaction. [PDF]
Nemčeková K+10 more
europepmc +1 more source